abstract
- A large fraction of young breast cancer patients are concerned about their chances of future fertility. Chemotherapy often results in premature ovarian failure, particularly in women over the age of 35. Recent trials have suggested that concomitant administration of gonadotropin-releasing hormone agonists (GnRHa) with chemotherapy reduces the risk of premature ovarian failure. This option is currently endorsed by several international and local guidelines, and in some countries it is being covered by healthcare insurance as well. In this chapter, we discuss the clinical data supporting the use of GnRHa in early breast cancer for ovarian protection and fertility preservation.